AMS IS THE INDUSTRY LEADER IN STRATEGIC INTELLIGENCE SOFTWARE FOR COMBATTING EMERGING HIGH-COST CLAIM ISSUES
What We Do:
AMS delivers crucial insight into catastrophic diagnoses, specialty pharmaceutical, and implant price transparency through clinically vetted, predictive financial analytics with near real-time data.
Who We Serve:
AMS serves multiple stakeholders in the medical claims payment chain, including commercial and governmental payers, Stop Loss and Reinsurance Carriers, MGUs, Medical Management Firms, Health Plans, TPAs, HMOs, Taft-Hartley Plans, workers compensation, and auto medical carriers.
WHO IS USING THE PREDICT SUITE
THE PREDICT SUITE
AMS’ Web-based directories that allow
clients to predict, evaluate and manage high dollar healthcare claims.
PREDICT
Predict costs and clinical treatments for high dollar diagnoses with an on demand decision support solution delivering in-depth clinical information, empirical insight and key financial analytics.
EVALUATE
Evaluate cost data, FDA approved indications, notable off-label usage, adult/pediatric dosing regimens, manufacturer rebates, specialty drug coding and price trends.
MANAGE
Manage highly inflated implant claims by leveraging detailed clinical and financial metrics with the only online, fully- transparent implant cost directory in the industry.
PREDICT SUITE MEMBERSHIP HAS ITS BENEFITS
100%
Reference Rate
Predict Suite Members willing + eager to connect with prospects
99%
Members
Retained
We have retained 99% of our members
13,000
Clinical/Financial Iterations
Including rules, off label + orphan drug uses, price benchmarks and CPT codes
100s
Weekly Hours
Saved
We have saved our clients and members 100s of weekly hours in research and underwriting
AMS Blog
-
About a decade ago, it wasn’t uncommon for the babies in the neonatal intensive-care unit at Intermountain Healthcare’s Dixie Regional Medical Center to receive as many as 78 tests or treatments during their stay. Each intervention can cause the fragile baby pain and increase the likelihood of infection, ultimately lengthening hospital stays and overall costs…. Read More »
-
Gene Therapy Advances To Better Treat ‘Bubble Boy’ Disease
April 19, 2019
Sometimes rare diseases can let scientists pioneer bold new ideas. That has been the case with a condition that strikes fewer than 100 babies a year in the United States. These infants are born without a functioning immune system. The disease is called severe combined immunodeficiency, or SCID. “It was made famous in the mid… Read More »